Compare ATYR & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | FORA |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 66.2M |
| IPO Year | 2015 | N/A |
| Metric | ATYR | FORA |
|---|---|---|
| Price | $0.88 | $2.08 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 26.6K |
| Earning Date | 03-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $190,000.00 | ★ $28,106,911.00 |
| Revenue This Year | N/A | $51.82 |
| Revenue Next Year | $18,728.88 | $7.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $0.64 | $1.64 |
| 52 Week High | $7.29 | $4.03 |
| Indicator | ATYR | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 44.12 |
| Support Level | $0.82 | $2.07 |
| Resistance Level | $0.94 | $2.10 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 54.37 | 28.57 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.